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The main cause of morbidity and mortality in Fanconi anemia patients is the development of bone marrow (BM) failure; thus
correctionofhematopoietic stemcells (HSCs)throughgenetransfer approaches would beneﬁt FA patients. However, gene therapy
trials for FA patients using ex vivo transduction protocols have failed to provide long-term correction. In addition, ex vivo cultures
have been found to be hazardous for FA cells. To circumvent negative eﬀects of ex vivo culture in FA stem cells, we tested the
correctiveabilityofdirectinjectionofrecombinantlentiviralparticlesencodingFancC-EGFPintofemursofFancC−/− mice.Using
this approach, we show that FancC−/− HSCs were eﬃciently corrected. Intrafemoral gene transfer of the FancC gene prevented
the mitomycin C-induced BM failure. Moreover, we show that intrafemoral gene delivery into aplastic marrow restored the bone
marrow cellularity and corrected the remaining HSCs. These results provide evidence that targeting FA-deﬁcient HSCs directly in
their environment enables eﬃcient and long-term correction of BM defects in FA.
1.Introduction
Fanconi anemia (FA) is a rare autosomal or X-linked genetic
disease manifested by early bone marrow (BM) failure,
congenital abnormalities and an increased risk of cancer [1–
3]. Currently, FA is deﬁned by 13 genes/complementation
groups (FA from A to N) [4], and although the speciﬁc func-
tion of each FA protein is largely unknown, they cooperate in
a common cellular pathway by forming protein complexes
involved in DNA damage responses, apoptosis, and stem
cell function [3, 5, 6]. The primary clinical phenotype
and major cause of death in patients is the progressive
depletion of hematopoietic stem cells (HSCs) leading to
BM failure. While the long-term curative treatment of the
hematological manifestation of the disease is allogeneic BM
or cord blood stem cell transplantation, this procedure
carries a substantial risk with HLA-matched unrelated BM
donors [7–9]. Furthermore, FA patients are hypersensitive
to the conditioning regiment and present a higher incidence
of secondary malignancies. Thus an alternative curative
treatment for FA patients might be gene transfer into HSC.
Since stem and progenitor cells can easily be harvested
from the BM or peripheral blood, ex vivo transduction
protocols using viral vectors as a delivery system have been
attempted in FA patients but have failed to provide long-
term hematopoietic reconstitution from gene-corrected cells
[10, 11]. Several reasons may account for the poor success
rate of these trails, for instance, the low availability of
HSC found in FA patients even before severe pancytopenia
[10], the reduced reconstitution ability and self-renewal
capacity of FA-deﬁcient HSC following culture [12, 13],
the development of aberrant clones of FA-deﬁcient HSC
following ex vivo culture [13], as well as defective homing
properties of FA-deﬁcient BM cells [14]. Although rapid
transduction of FA cells using short-term culture [15]o r
culture in the presence of an antioxidant [16]i m p r o v e dF A
cell survival, these approaches still make use of cytokines
a n dg r o w t hf a c t o r st h a tm a ya ﬀect long-term HSC function
[12, 17]. Thus, targeting HSC directly in their environment
would ensure maintenance of their function and enable the2 Anemia
correction of the remaining stem cells. The feasibility of
in vivo gene transfer by direct intrafemoral, or intrabone
marrow, injection of adeno-, retro-, and lenti-viral particles
into mice has recently been demonstrated [18, 19]. These
studiesshowedeﬃcienttransductionofHSCswithdetection
of the GFP transgene in progenitors and cell lineages. Using
this in vivo gene delivery approach, we present data showing
eﬃcient transduction of HSC and long-lasting FancC trans-
gene expression in FancC−/− mice following intrafemoral
(IF) injections of recombinant lentiviral vector (LV). In
addition,weshowthattransducedHSCretaintheirpotential
to diﬀerentiate into all blood cell lineages and maintain their
reconstitution ability as shown by primary transplants. In
vivo delivery of FancC-coding LV particles fully restored
resistance to DNA crosslinking agents and prevented BM
failure in FancC−/− mice. Furthermore, reversal of aplasia
was observed following IF injection of the FancC transgene
into BM-depleted FancC−/− mice. This preclinical study
supports in vivo gene delivery of recombinant LV particles
as a means to treat the hematopoietic defect in FA patients.
2. Methods
2.1. Lentivirus Production. The three-plasmid expression
system containing the packaging plasmid pCMVR8.91 pro-
viding the Gag, Pol, Tat, and Rev proteins, the envelope-
coding plasmid pMD.G providing the vesicular stomati-
tis virus glycoprotein (VSV-G), and the transfer vector
pSinPGK-EGFP was a gift from D. Trono [20]. The murine
FancCgenewasclonedinfusiontotheEnhancedGreenﬂuo-
rescent protein (EGFP; pEGFP-C1; Clontech) and subcloned
into the LV transfer plasmid (pSIN-FancC-EGFP). Func-
tionality of the FancC-EGFP fusion protein was tested in
FANCC mutant lymphoblastoid cells (HSC536; gift from Dr.
M. Buchwald) and found to fully correct the DNA crosslink
sensitivity (Figure 1(a)). LV particles were produced by
triple-transient Ca3PO4 transfection into HEK293T cells.
Supernatants containing particles were collected, ﬁltered,
and concentrated by ultracentrifugation (90 minutes at
30,000rpm). The infectivity of concentrated viral vec-
tor stocks was determined on HeLa cells and scored by
FACS analysis for EGFP expression. Titers obtained ranged
between 7 to 10 ×107 transduction units per mL.
2.2. Intrafemoral Injections and Flow Cytometric Analysis. IF
injection of LV particles was performed according to the
IF cell transplantation procedure described by Mazurier et
al. [21]. Brieﬂy, 3- to 5-month-old wild type, FancC−/−,o r
FancA−/− mice (C57BL/6J, 11th generation of backcrosses;
CD45.2+) were anesthetized and 25uL of concentrated
LV supernatant (1.8 to 2.5 × 106 transduction units per
femur) were injected through the joint into the right femur
using a 28.5-gauge needle. In some experiments, mice were
preconditioned with MMC (0.3mg/kg) ﬁve days prior to
IF injection to induce BM aplasia as described previously
[22]. To determine the correction potential of the FancC-
EGFP transgene, injected mice were subjected to weekly
s.c. injection of MMC (0.3mg/kg) as previously described
[22]. To evaluate the transduction eﬃcacy, peripheral blood
and BM cells were collected at various time points and
analyzed by multiparameter ﬂow cytometry (FACS Calibur
cytometer; BD Biosciences) for FancC-EGFP expression and
lineage markers (CD11b-PerCP or CD45R-PerCP and Ly-
6G-APC or CD5-APC; BD Biosciences). All animal proce-
dures were performed according to protocols approved by
the Animal Care Committee of Laval University, Qu´ ebec,
Canada.
2.3. Transplantation Procedures. To determine the recon-
stitution potential of transduced HSC, IF-injected mice
were sacriﬁced, and BM cells were collected at 4 months
post injection or following 15 weeks of MMC treatment
and were transplanted (2 × 106 cells) into lethally irra-
diated recipient mice (B6.SJL-PtrcaPep3b/BoyJ; CD45.1).
Reconstitution ability of donor cells was monitored as
previously described [12]. Brieﬂy, peripheral blood cells
were collected once per month for 4 months. White blood
cells were stained with CD45.2-PE (donor origin), CD11b-
PerCP (monocytes), or CD45R-PerCP (B lymphocytes) and
Ly-6G-APC (granulocytes) or CD5-APC (T lymphocytes)
and analyzed by multiparameter ﬂow cytometry. Recipient
mice received antibiotics one week prior to irradiation and
transplantation.
2.4. Colony Forming Cell Assay. Hematopoietic committed
progenitorcellassayswereperformedasdescribedpreviously
[22]. Brieﬂy, BM cells were collected from femurs of injected
or transplanted mice where 2 to 5 × 104 cells per mL were
seeded in complete methylcellulose medium according to
the manufacturer (Stem Cell Technology) and incubated
for seven to 10 days at 37
◦C, 5% CO2. Total colonies were
counted and depicted as colony forming cells (CFCs). For
correction potential of transduced cells, 5nM MMC was
added to the methylcellulose cultures at plating as previously
described [22].
2.5. Histological Analysis. Mice were euthanized and tissues
were immediately collected and placed in 10% neutral
buﬀered formalin. Fixed tissues were embedded in paraﬃn,
sectioned at 4μm, and stained with hematoxylin-eosin using
standard methods. For the detection of transduced cells,
immunohistochemistry was performed on tissue sections
from gonads, liver, spleen, and thymus. Breiﬂy, sections
were deparaﬃnised, rehydrated, and incubated overnight
with an anti-GFP rabbit polyclonal antibody (Invitrogen)
diluted 1 : 3000. Antibody detection was carried out with
the IDetect Super Stain System (IDLabs) and counterstained
with Mayer’s hematoxylin. Tissue sections were visualized
at magniﬁcation of 200× using a Nikon E800 microscope
equipped with a CCD camera (Hamamastu Orca ER;
Nikon).
3. Results
3.1. Stable Expression of the FancC-EGFP Transgene following
Intrafemoral Injection of Recombinant Lentiviral Particles. ToAnemia 3
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Figure 1: Corrective ability of the FancC-EGFP transgene. (a) FA group C mutant cells (HSC536) were transduced with either pSINFancC
and pSINFancC-EGFP or pSINEGFP recombinant lentiviral particles. Growth survival of transduced cells as compared to normal cells
(HSC93) was established with various concentrations of mitomycin C (MMC). Each point represents the mean ± SEM of three separate
experiments. Absence of SEM bars represents values too low to appear in the graph. (b) EGFP transgene expression in bone marrow cells
of intrafemorally injected wild type and FancC−/− mice ﬁve months following IF injections. Each dot represents the EGFP expression of an
individual IF-injected mouse. Horizontal line: mean value. ∗P<. 05.
determinethefeasibilityofinvivoBMstemcellgenetransfer
as a means to correct the Fanconi anemia stem cell defect,
we ﬁrst designed an HIV-derived LV coding for the murine
FancC transgene in fusion with the EGFP reporter protein.
This FancC-EGFP fusion construct was tested and found to
phenotypically correct FANCC mutant cells (Figure 1(a)).
We next explored the potential of in vivo BM cell gene
transfer through IF injections of recombinant LV particles
coding for EGFP directly into femurs of adult wild type and
FancC−/− mice. EGFP expression was analyzed in peripheral
blood at two weeks after injection. Cytometric analysis of
peripheral blood showed 5% to 10% of EGFP-positive cells
in only a few animals (4 out of 8 mice; data not shown).
Cytometric analysis of peripheral blood was then performed
each month. Levels of EGFP-positive cells in each animal
did not change before the third month. All mice were
then sacriﬁced at 5 months following IF injections, and
surprisingly, all mice showed EGFP-positive cells in their
blood and BM ranging from 5% to 50% of cells validating
this technique (Figure 1(b)). No side eﬀects were noted in
IF-injected animals at any time during the procedure.
To determine the corrective ability of intrafemoral
gene transfer, recombinant FancC-EGFP LV particles were
injected directly into femurs of adult wild type, FancC−/−,
and FancA−/− mice. Figure 2(a) shows the experimental
design where 6 to 10 mice from each genotype were injected
with recombinant FancC-EGFP LV particles. Peripheral
blood cells from IF-injected mice were analyzed each month
for EGFP expression. Low levels of transgene expression
were found in blood cells from all mice at one month
following injection ranging from 5% to 20% (Figure 2(b)).
The mean number of EGFP-FancC expressing cells became
higher over time in all mice but more dramatically in
FancC−/− mice (mean of 42% at 4 months) compared to
WT or FancA−/− mice (mean of 10% and 12%, resp.). In
addition, FancC-EGFP transgene expression was detected
in both myeloid and lymphoid blood cell lineages from all
injected mice suggesting that progenitors were eﬃciently
transduced (Figure 2(c)).
3.2. Intrafemoral Gene Transfer Prevents Mitomycin C-
I n d u c e dB o n eM a r r o wF a i l u r ei nFancC−/− Mice. To deter-
mine the corrective potential of intrafemoral gene transfer
into BM cells, half of the IF-injected mice from each
genotype (see experimental design in Figure 2(a))w e r e
treated weekly with 0.3mg/kg mitomycin C (MMC), a dose
known to induce progressive BM failure in FA mutant
mice [22]. Wild type mice were used as positive controls
and FancA−/− mice as negative controls since they were
injected with an uncomplementing gene. MMC treatment
was started seven weeks after IF-mediated FancC-EGFP gene
transfer. FancC-EGFP expression in peripheral blood cells
w a sm e a s u r e db e f o r eM M Ct r e a t m e n ta n de v e r ym o n t h
following treatment. All mice showed low levels of FancC-
EGFP-positive cells before the start of MMC treatments
(Figure 3(a)).FancC-EGFP-positivecellsslightlyincreasedin
WTmiceaftertheﬁrstMMCtreatment(twomonthspost-IF4 Anemia
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Figure 2: Intrafemoral gene transfer into BM of FA mutant mice. (a) Illustration of the experimental protocol used to determine
the corrective potential of intrafemoral LV-mediated gene transfer into BM cells. Wild type (WT), FancC−/− and FancA−/− mice were
intrafemorally injected with recombinant FancC-EGFP lentiviral particles. Transgene expression was monitored each month for at least four
months. At 7 weeks following IF injections, each group of mice was divided where half of the mice were treated with MMC for 15 weeks
(weakly injection of 0.3mg/kg). (b) FancC-EGFP transgene expression in peripheral blood cells of IF injected WT, FancC−/−,a n dFancA−/−
mice as a function of time. Each dot represents the FancC-EGFP expression of an individual IF-injected mouse. Horizontal line: mean value.
∗P<. 02. (c) Representative FACS proﬁles of FancC-EGFP expression in FancC−/− peripheral blood cell lineages at four months after IF
injection.Anemia 5
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Figure 3: Intrafemoral gene transfer prevents MMC-induced BM aplasia. (a) FancC-EGFP transgene expression in peripheral blood cells
of IF-injected wild type (WT), FancC−/−,a n dFancA−/− mice as a function of time. Each dot represents the FancC-EGFP expression of an
individual IF-injected mouse. The arrow represents the start of weekly MMC injections (0.3mg/kg). Horizontal line: mean value. ∗P<. 02.
(b) Survival curves of IF-injected FancC−/− (n = 5) and FancA−/− (n = 3) mice following MMC treatments. Control FancC−/− mice
represent uninjected mice treated weakly with MMC (n = 22). (c) Representative histological appearances of the sternum from injected
mice after 15 weeks of MMC treatment. Hematoxylin-eosin staining: original magniﬁcation 200×.
injections), but dramatically increased in all FancC−/− IF-
injected mice compared to both WT and FancA−/− mice.
We have previously shown that FancC−/− mice of mixed
background died within eight weeks of MMC treatment
[22], whereas FancC−/− mice of C56BL/6 background died
within 10 weeks (Control FancC; Figure 3(b)). We found
that all IF-injected FancC−/− mice survived the 15 weeks
of MMC treatment thus, conﬁrming the protective eﬀect of
IF-mediated gene transfer into BM cells (Figure 3(b) and
Table 1). As expected, FancA−/− mice injected with FancC-
EGFP recombinant LV particles died of MMC-induced BM
failure following eight weeks of MMC treatment for lack of6 Anemia
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Figure 4: Functional correction of BM progenitors following LV-mediated FancC-EPFP gene transfer. CFC analysis of BM cells from
IF-injected mice at four months following injection (a) and following chronic MMC treatments (b). Percent CFC numbers with MMC
compared to cultures without MMC. Controls represent noninjected WT or FancC−/− mice. Data represent the mean ± SEM obtained
from at least 3 mice in each group each done in triplicates. ∗P<. 00005. (c) and (d) Representative cytometric proﬁles of FancC-EGFP
expression in BM cells from IF-injected mice at four months following injection (c) and following chronic MMC treatment (d). (e) and
(f) Representative cytometric proﬁles of FancC-EGFP expression in Sca1-positive BM cells from IF-injected FancC−/− mice at four months
following injection (e) and following chronic MMC treatment (f).
Table 1: Number of mice that survived MMC-treatments after LV-mediated intrafemoral gene transfer.
Wild type FancC−/− FancA−/−
Pre-conditioned∗ Pre-conditioned∗ Preconditioned
5/5 6/6 5/5 6/6 3/3 3/4¶
Weekly MMC
(0.3mg /kg)† 5/5 6/6 5/5 5/6‡ 0/3 0/4
Number of mice that survived/number of mice IF-injected with EGFP-FancC recombinant viral particles.
∗ Mice were pre-conditioned with MMC (0.3mg/kg) 4 days prior to IF injection.
† Weekly treatment with MMC for 15 weeks.
‡ 1 FancC−/− mouse died due to bleeding during blood collection.
¶ 1 FancA−/− mouse died 15 days following IF injection from a mishap unrelated to vector administration.
correction. BM sections from MMC-treated mice showed
that IF injection of FancC-EGFP prevented BM aplasia in
FancC−/− mice and maintained the presence of all cell
types including megakaryocytes (Figure 3(c)). As expected,
a marked reduction in cellularity with depletion of all cell
typeswasobservedinFancA−/− micewhereasnoremarkable
eﬀects were observed in wild type mice. This dramatic
reduction in BM cellularity resembled the long-term chronic
exposure to low doses of MMC in FA mutant mice as
previously reported [22].Anemia 7
3.3. Functional Correction of Progenitors and Stem Cells
from FancC−/− Mice. To determine if phenotypic correction
occurred at the level of progenitors and stem cells, CFC
assays were performed using total BM cells collected from
IF-injected mice at 4 months following IF-injection or after
chronic (15 weeks) MMC treatments. Results show that
FancC−/− progenitors obtained from IF-injected mice were
corrected for their MMC sensitivity showing wild type levels
of CFCs in the presence of MMC suggesting that progenitors
were corrected for their MMC sensitivity (Figure 4(a)).
Chronic exposure to MMC has been previously shown to
dramaticallyreduceFancC−/− BMCFClev elstolessthan1%
of normal [22]. CFC assays performed using total BM cells
derived from MMC-treated FancC-EGFP-injected FancC−/−
mice showed CFC levels similar to those of wild type
mice indicating that progenitors were resistant to chronic
exposure to MMC (Figure 4(b)).
To determine if the phenotypic correction also occurred
at the level of repopulating stem cells, transplantation
procedures were performed using puriﬁed unfractionated
BM cells obtained from wild type, FancC−/−,a n dFancA−/−
IF-injected mice and from mice that survived chronic MMC
treatment. FancC-EGFP protein expression was measured
in total BM cells before transplants and found in the BM
of all IF-injected mice (Figures 4(c) and 4(d)). FancC-
EGFP protein expression was detected in Sca1-positive BM
cells suggesting that progenitor/stem cells were transduced
(Figures 4(e) and 4(f)). Two million of total BM cells were
transplanted into lethally irradiated recipient congenic mice.
Chimerism expressed as CD45.2-positive cells was detected
in all recipients, those that received BM cells from untreated
(Figure 5(a)) and from MMC-treated mice (Figure 5(b)).
Expression of FancC-EGFP was detected in the majority of
peripheral blood cells of donor origin (Figure 5(c)). FancC-
EGFP transgene expression in peripheral blood cells was
maintained throughout the observation period in all recip-
ients indicating that intrafemoral gene transfer eﬃciently
targetedtherepopulatingstemcells.Inaddition,theseresults
suggest that the targeted stem cells were able to sustain
chronic MMC treatment.
3.4. Correction of Hematopoiesis in FancC−/− Mice with
Bone Marrow Aplasia. Since FA patients were found to
have reduced numbers of stem/progenitor cells early in the
disease possibly before pancytopenia [10], we tested the
corrective potential of IF-mediated gene transfer into a more
clinically relevant disease setting. Thus, FancC−/− mice were
preconditioned with one MMC injection (0.3mg/kg) one
week prior to IF-mediated FancC-EGFP gene transfer (see
experimental design in Figure 6(a)). We previously showed
that one MMC treatment in FancC−/− mice reduced the BM
c e l l u l a r i t yb y7 0 %[ 22], decreased the short-term reconsti-
tutingcells(Lin
−c-Kit+Sca1+CD34+ stemcellpopulation)by
85% as compared to untreated mice, and decreased colony
forming cells (CFCs) and long-term culture-initiating cells
(LTC-IC) to levels of 16% and 33% of untreated mice,
respectively [23]. Wild type, FancC−/−,a n dFancA−/− pre-
conditioned mice (8 to 12 mice per group) were IF-injected
with recombinant FancC-EGFP LV particles. FancC-EGFP
expression was monitored monthly over a period of four
months in the peripheral blood of injected animals. FancC-
EGFP transgene expression was detected in all IF injected
mice (Figure 6(b)). FancC-EGFP positive peripheral blood
cells increased over time to more than 90% in FancC−/−
mice at four months following IF injections. This increase
in FancC-EGFP positive cells was also observed in FancA−/−
mice possibly due to transduction of the remaining BM
stem/progenitor cells and/or clonal ampliﬁcation. Concomi-
tant with high numbers of FancC-EGFP positive peripheral
blood cells, cells from both myeloid and lymphoid lineages
expressed the FancC-EGFP transgene (Figure 6(c)).
To determine the corrective potential of IF-mediated
gene transfer into aplastic marrow, half of the pre-
conditioned wild type, FancC−/−,a n dFancA−/− mice were
submitted to chronic MMC exposure at seven weeks follow-
ing IF injection of FancC-EGFP recombinant LV particles.
FancC-EGFP expression was monitored monthly over a
period of 15 weeks in the peripheral blood (Figure 7(a)),
with all injected animals presenting FancC-EGFP-positive
blood cells over the four months period. Variation in levels
of cells expressing the transgene was observed in mice
from all genotypes used. All wild type and FancC−/− mice
survived the chronic exposure to MMC while FancA−/−
mice died between eight and 11 weeks following MMC
treatment (Figure 7(c) and Table 1). FancC-EGFP expres-
sion was detected in all blood cell lineages tested from
injected FancC−/− and wild type mice at 15 weeks of
MMC exposure (Figure 7(b)) implying that stem/progenitor
cells were eﬃciently transduced and corrected for their
sensitivity to MMC. BM sections from preconditioned
mice at four months following IF injections showed that
FancC−/− mice, but not FancA−/− replenished their BM
and maintained the presence of all cell types including
megakaryocytes (Figure 7(d)). In addition, BM sections of
animalsfollowingchronicexposuretoMMCshowedthatIF-
injectedFancC−/−,butnotFancA−/−,micereplenishedtheir
BMcellularityasinwildtypemice.Furthermore,transplants
performed with BM cells from these pre-conditioned mice
at four months following IF injection showed that the
remaining stem cells of FancC−/− mice with BM aplasia
were transduced thus enabling them to maintain their
reconstitution potential (Figure 8). Collectively, these results
clearly indicate that the remaining stem/progenitor cells of
an aplastic marrow can be eﬃciently transduced, and thus
genetically corrected through IF injection of recombinant LV
particles.
4. Discussion
Mouse models of FA have been extensively studied in the
context of gene therapy protocols using various targeting
viral vectors [24–27]. All of these studies have shown that ex
vivo gene transfer is feasible as treatment for the hematopoi-
etic defects observed in FA. However, in the context of
clinical gene therapy, suﬃcient numbers of hematopoietic
stem/progenitorscellsfromFApatientsarediﬃculttoobtain8 Anemia
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Figure 5: Reconstitution ability of intrafemorally transduced HSC following transplants. Percent donor chimerism (CD45.2-positive cells)
in peripheral blood cells from recipients transplanted with total BM from (a) IF-injected WT, FancC−/−,o rFancA−/− mice and (b) from
WT or FancC−/− mice that received chronic MMC treatments at 7 weeks following IF-injection as a function of time. Each dot represents
donor chimerism of an individual recipient. Horizontal line: mean value. (c) Representative cytometric proﬁles of FancC-EGFP expression
in peripheral blood cell lineages from transplanted mice at 3 months following transplantation with BM cells from FancC−/− IF-injected
animals.Anemia 9
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Figure 6: Corrective potential of intrafemoral gene transfer into FA mice with BM aplasia. (a) Illustration of the experimental protocol used
to determine the corrective potential of intrafemoral LV-mediated gene transfer into aplastic BM. Wild type (WT), FancC−/−,a n dFancA−/−
mice were preconditioned with MMC ﬁve days prior to intrafemoral injection of recombinant FancC-EGFP lentiviral particles. At 7 weeks
following IF injections, each group of mice was divided where half of the mice were treated with MMC for 15 weeks (weakly s.c. injection of
0.3mg/kg). (b) Transgene expression was monitored each month for four months: FancC-EGFP transgene expression in peripheral blood
cells of preconditioned IF-injected wild type (WT), FancC−/−,a n dFancA−/− mice. Each dot represents the FancC-EGFP expression of an
individual IF-injected mouse. Horizontal line: mean value. ∗P<. 05. (c) Representative cytometric proﬁles of FancC-EGFP expression in
peripheral blood cell lineages from FancC−/− preconditioned IF-injected mice at four months following in vivo gene transfer.
even following G-CSF-mobilization [28]. Furthermore, ex
vivo culture for gene transfer is deleterious for FA cells and
in retrospect would possibly explain the poor success rate of
earlier gene therapy trials in FA patients [11–13, 17]. Our
data now provides an alternative to ex vivo gene transfer
approaches showing the eﬃcacy of direct intrafemoral gene
delivery in correcting the hematopoietic defects in FA.
Ourresultsdemonstratethatsustainedlong-termexpres-
sion of the FancC transgene is achievable using a direct
in vivo gene transfer approach. By using LV to deliver the
FancC-EGFP transgene, hematopoietic stem and progenitor
cells were eﬃciently transduced in their environment as
shown by the maintenance of FancC-EGFP expression in
various peripheral blood cell types from IF-injected animals
over a four-month period and following transplants.
Transduced stem and progenitor cells were functionally
corrected for their MMC sensitivity as shown by wild type
levels of CFC in the presence of MMC, thus showing10 Anemia
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Figure 7:PreventionofBMfailurefollowingIFgenetransferintomicewithBMaplasia.(a)FancC-EGFPtransgeneexpressioninperipheral
blood cells of preconditioned IF-injected wild type (WT), FancC−/−,a n dFancA−/− mice that received chronic MMC treatments at 7 weeks
following IF-injection as a function of time. The arrow represents the start of weekly MMC injections (0.3mg/kg). Each dot represents the
FancC-EGFP expression of an individual IF-injected mouse. Horizontal line: mean value. (b) Representative cytometric proﬁles of FancC-
EGFP expression in peripheral blood cell lineages from FancC−/− preconditioned IF-injected mice at 15 weeks following weekly MMC
treatment. (c) Survival of preconditioned IF-injected FancC−/− (n = 6) and FancA−/− (n = 4) mice following MMC treatments. Control
FancC−/− mice represent uninjected mice treated weakly with MMC (n = 22). (d) Representative histological appearances of the sternum
from preconditioned and IF-injected mice at four months following IF injections (no treatment) and at 15 weeks following weekly MMC
treatment (+ MMC). Hematoxylin-eosin staining: original magniﬁcation 200×.
that the inserted transgene is functional in correcting
this defect. In addition, mice intrafemorally injected with
the FancC-EGFP transgene were resistant to the MMC-
induced progressive BM failure. Colony formation assays
and histological analysis of BM tissues from the sternum
not only conﬁrmed the resistance to MMC treatment but
also showed that FancC−/− mice replenished their BM.
In addition, the fact that the sternum showed replenished
BM cellularity indicates that corrected stem/progenitor cells
migrated from the injected site to other BM sites. AnalysisAnemia 11
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Figure 8: Reconstitution ability of intrafemorally transduced HSC following transplants: percent donor chimerism (CD45.2-positive cells)
in peripheral blood cells from recipients transplanted with total BM from preconditioned IF-injected WT and FancC−/− mice as a function
oftime.Eachdotrepresentsdonorchimerismofanindividualrecipientwithtentofourteenmicepergenotype.Horizontalline:meanvalue.
of transgene expression in both femurs and in the thymus
and spleen (data not shown) also conﬁrmed the migration
of transduced hematopoietic cells to other hematopoietic
t i s s u e sa sp r e v i o u s l yr e p o r t e d[ 18, 19]. These previous gene
markings studies also showed that the hematopoietic system
remained the main target of IF-mediated gene transfer as
compared to other nonhematopoietic tissues such as gonads
where undetectable to near background levels of transgene
have been reported [18, 19]. We have analyzed tissues from
the liver and gonads by immunohistochemistry using an
anti-GFP antibody and did not ﬁnd any positive cells in the
tissue sections tested (data not shown).
We used weekly injection of MMC as a measure of func-
tional correction of transduced stem cells. This treatment
is probably more deleterious in view of FA cells inability
to repair MMC-induced DNA lesions than the pressure
from the environment that FA patients are subjected to.
Thus, resistance to chronic MMC treatment in IF-injected
FancC−/− mice supports the notion that corrected cells have
a selective advantage over noncorrected cells in maintaining
hematopoiesis.
We also applied this in vivo gene transfer approach in a
relevant human disease setting where FancC−/− mice were
preconditioned with MMC to induced BM aplasia before
IF injection of recombinant FancC-EGFP LV particles. We
had previously shown that MMC treatment reduces BM
cellularity by 70% and both short- and long-term reconsti-
tuting HSC by 85%, thus mimicking aplastic BM found in
FA patients [22]. Using this model, we were able to show
thattheremainingstemcellsweretransducedandgenetically
corrected for their hematopoietic defects showing multi-
lineage reconstitution. Suprisingly, levels of EGFP-FancC
positive cells increased in both FancC−/− and FancA−/−
preconditionedanimalsovertimesuggestingtransductionof
the remaining progenitor/stem cells and consequently clonal
ampliﬁcation of these transduced cells. However, IF-injected
aplastic FancC−/− mice but not FancA−/− that received
weekly MMC treatment survived the treatment and showed
replenished BM cellularity and maintained the presence of
all cell types. Therefore, our results indicate that the few
remaining stem cells of an aplastic mouse could be corrected
through intrafemoral injection of recombinant LV, thus
maintaining eﬃcient long-term hematopoiesis.
During the course of these experiments, we did not
observe adverse eﬀects of the procedure nor did we detect
leukemia or myelodysplasia in IF-injected and transplanted
mice also shown by normal BM architecture in IF-injected
mice and transplanted recipients. Although leukemia has
rarely been observed in FA mice, clonal evolution reminis-
cent of myelodysplasia has been observed in FancC−/− mice
at 16 months following an ex vivo transduction approach
using retroviral vectors [13, 29] further supporting that in
vivo gene transfer into HSC in their environment prevents
deleteriouseﬀectscausedbyexvivomanipulation.Theuseof
LV,whichcantransducedquiescentcells[30]thusprecluding
stem cell activation, may also be less detrimental to FA
cells. Longer follow-up and studies in larger animals may be
needed to rule out possible deleterious eﬀects of insertional
mutagenesis using LV-mediated in vivo gene transfer. There
areseveralongoingandupcomingLV-mediatedgenetherapy
clinical trials for the treatment of various diseases including
FA [31]. One such trial has shown eﬃcacious correction
of X-linked adrenoleukodystrophy and expression of the
transgene at 30 months after infusion without adverse
eﬀects [32]. Although most of the current LV-mediated gene
therapy trials use ex vivo transduction protocols, the clear
clinical beneﬁts recently reported suggest that LV-mediated
gene transfer may be beneﬁcial for the treatment of FA.
In conclusion, this study demonstrates that LV-mediated
in vivo gene therapy for the treatment of Fanconi anemia
is feasible even following BM aplasia. The resolution of the
BM defect following in vivo gene delivery in preconditioned
FancC miceprovidesthebasisforanewalternativetreatment
for FA patients with limited numbers of stem/progenitor
hematopoietic cells. This preclinical study therefore pro-
vides the basis for a gene transfer strategy for targeting12 Anemia
HSC in their environment without the need for ex vivo
manipulations or the need for conditioning regimen and
transplantation procedures.
Acknowledgments
The authors wish to thank Dr. D. Trono for providing the
SIN-Lentiviral vectors, Monica Doedens for her technical
assistance with IF injections, and Caroline Huard for her
assistance with the ﬁgures. This work was supported by
a grant from the Canadian Institutes of Health Research
(CIHR), a CIHR junior investigator award (M.C.), FRSQ
junior II, and senior investigator awards (M.C.). Additional
supportwasprovidedbytrainingawardsfrom“LaFondation
des ´ etoiles” to O. Habi
References
[1] N. Young, Bone Marrow Failure Syndromes, W.B. Saunders,
2000.
[2] B. P. Alter, “Cancer in Fanconi anemia, 1927–2001,” Cancer,
vol. 97, no. 2, pp. 425–440, 2003.
[3] M. D. Tischkowitz and S. V. Hodgson, “Fanconi anaemia,”
Journal of Medical Genetics, vol. 40, no. 1, pp. 1–10, 2003.
[4] R. D. Kennedy and A. D. D’Andrea, “The Fanconi ane-
mia/BRCA pathway: new faces in the crowd,” Genes and
Development, vol. 19, no. 24, pp. 2925–2940, 2005.
[5] T. Taniguchi and A. D. D’Andrea, “Molecular pathogenesis of
Fanconi anemia: recent progress,” Blood, vol. 107, no. 11, pp.
4223–4233, 2006.
[6] K. Sii-Felice, O. Etienne, F. Hoﬀschir, et al., “Fanconi DNA
repair pathway is required for survival and long-term mainte-
nance of neural progenitors,” The EMBO Journal, vol. 27, no.
5, pp. 770–781, 2008.
[7] Ph. Guardiola, R. Pasquini, I. Dokal, et al., “Outcome of
69 allogeneic stem cell transplantations for Fanconi anemia
using HLA-matched unrelated donors: a study on behalf of
the European Group for Blood and Marrow Transplantation,”
Blood, vol. 95, no. 2, pp. 422–429, 2000.
[8] E. Gluckman, “Bone marrow transplantation in Fanconi’s
anemia,” Stem Cells, vol. 11, pp. 180–183, 1993.
[9] M. Kohli-Kumar, C. Morris, C. DeLaat, et al., “Bone marrow
transplantation in Fanconi anemia using matched sibling
donors,” Blood, vol. 84, no. 6, pp. 2050–2054, 1994.
[10] P. F. Kelly, S. Radtke, C. von Kalle, et al., “Stem cell collection
and gene transfer in Fanconi anemia,” Molecular Therapy, vol.
15, no. 1, pp. 211–219, 2007.
[11] J. M. Liu, S. Kim, E. J. Read, et al., “Engraftment of
hematopoietic progenitor cells transduced with the Fanconi
anemia group C gene (FANCC),” Human Gene Therapy, vol.
10, no. 14, pp. 2337–2346, 1999.
[12] O. Habi, M.-C. Delisle, N. Messier, and M. Carreau, “Lack
of self-renewal capacity in FancC−/− stem cells after ex
vivo expansion,” Stem Cells, vol. 23, no. 8, pp. 1135–1141,
2005.
[13] L. S. Haneline, X. Li, S. L. M. Ciccone, et al., “Retroviral-
mediated expression of recombinant Fancc enhances the
repopulating ability ofFancC−/− hematopoietic stem cells and
decreases the risk of clonal evolution,” Blood, vol. 101, no. 4,
pp. 1299–1307, 2003.
[14] X. Zhang, X. Shang, F. Guo, et al., “Defective homing is
associated with altered Cdc42 activity in cells from patients
with Fanconi anemia group A,” Blood, vol. 112, no. 5, pp.
1683–1686, 2008.
[15] L. U. W. M¨ uller, M. D. Milsom, M.-O. Kim, A. Schambach, T.
Schuesler, and D. A. Williams, “Rapid lentiviral transduction
preserves the engraftment potential of Fanca−/− hematopoi-
etic stem cells,” Molecular Therapy, vol. 16, no. 6, pp. 1154–
1160, 2008.
[16] O. Cohen-Haguenauer, B. Peault, C. Bauche, et al., “In vivo
repopulationabilityofgeneticallycorrectedbonemarrowcells
from Fanconi anemia patients,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103,
no. 7, pp. 2340–2345, 2006.
[17] M. Aube, M. Lafrance, C. Charbonneau, I. Goulet, and M.
Carreau, “Hematopoietic stem cells from FancC−/− mice have
lower growth and diﬀerentiation potential in response to
growth factors,” Stem Cells, vol. 20, no. 5, pp. 438–447, 2002.
[18] C. S. McCauslin, J. Wine, L. Cheng, et al., “In vivo retroviral
gene transfer by direct intrafemoral injection results in
correctionoftheSCIDphenotypeinJak3knock-outanimals,”
Blood, vol. 102, no. 3, pp. 843–848, 2003.
[19] D. N. Worsham, T. Schuesler, C. von Kalle, and D. Pan, “In
vivo gene transfer into adult stem cells in unconditioned mice
by in situ delivery of a lentiviral vector,” Molecular Therapy,
vol. 14, no. 4, pp. 514–524, 2006.
[20] L. Naldini, U. Blomer, P. Gallay, et al., “In vivo gene delivery
and stable transduction of nondividing cells by a lentiviral
vector,” Science, vol. 272, no. 5259, pp. 263–267, 1996.
[21] F. Mazurier, M. Doedens, O. I. Gan, and J. E. Dick, “Rapid
myeloerythroid repopulation after intrafemoral transplanta-
tion of NOD-SCID mice reveals a new class of human stem
cells,” Nature Medicine, vol. 9, no. 7, pp. 959–963, 2003.
[22] M. Carreau, O. I. Gan, L. Liu, et al., “Bone marrow failure
in the Fanconi anemia group C mouse model after DNA
damage,” Blood, vol. 91, no. 8, pp. 2737–2744, 1998.
[ 2 3 ]M .C a r r e a u ,O .I .G a n ,L .L i u ,M .D o e d e n s ,J .E .D i c k ,
and M. Buchwald, “Hematopoietic compartment of Fanconi
anemia group C null mice contains fewer lineage-negative
CD34+ primitive hematopoietic cells and shows reduced
reconstitution ability,” Experimental Hematology, vol. 27, no.
11, pp. 1667–1674, 1999.
[24] F. Galimi, M. Noll, Y. Kanazawa, et al., “Gene therapy of
Fanconi anemia: preclinical eﬃcacy using lentiviral vectors,”
Blood, vol. 100, no. 8, pp. 2732–2736, 2002.
[ 2 5 ]K .A .G u s h ,K . - L .F u ,M .G r o m p e ,a n dC .E .W a l s h ,“ P h e n o -
typic correction of Fanconi anemia group C knockout mice,”
Blood, vol. 95, no. 2, pp. 700–704, 2000.
[26] P. Rio, J. C. Segovia, H. Hanenberg, et al., “In vitro phenotypic
correction of hematopoietic progenitors from Fanconi anemia
groupAknockoutmice,”Blood,vol.100,no.6,pp.2032–2039,
2002.
[27] K. Yamada, A. Ramezani, R. G. Hawley, et al., “Phenotype
correction of Fanconi anemia group A hematopoietic stem
cells using lentiviral vector,” Molecular Therapy,v o l .8 ,n o .4 ,
pp. 600–610, 2003.
[28] J.M.Croop,R.Cooper,C.Fernandez,etal.,“Mobilizationand
collection of peripheral blood CD34+ cells from patients with
Fanconi anemia,” Blood, vol. 98, no. 10, pp. 2917–2921, 2001.
[29] X. Li, M. M. Le Beau, S. Ciccone, et al., “Ex vivo culture of
FancC−/− stem/progenitor cells predisposes cells to undergo
apoptosis, and surviving stem/progenitor cells display cyto-
genetic abnormalities and an increased risk of malignancy,”
Blood, vol. 105, no. 9, pp. 3465–3471, 2005.Anemia 13
[30] M. Scherr and M. Eder, “Gene transfer into hematopoietic
stem cells using lentiviral vectors,” Current Gene Therapy, vol.
2, no. 1, pp. 45–55, 2002.
[31] J. D’Costa, S. G. Mansﬁeld, and L. M. Humeau, “Lentiviral
vectors in clinical trials: current status,” Current Opinion in
Molecular Therapeutics, vol. 11, no. 5, pp. 554–564, 2009.
[32] N. Cartier, S. Hacein-Bey-Abina, C. C. Bartholomae, et al.,
“Hematopoietic stem cell gene therapy with a lentiviral vector
inX-linkedadrenoleukodystrophy,”Science,vol.326,no.5954,
pp. 818–823, 2009.Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com